<?xml version="1.0" encoding="UTF-8"?>
<patent-document ucid="EP-1277489-B1" country="EP" doc-number="1277489" kind="B1" date="20140108" family-id="26590442" file-reference-id="256993" date-produced="20180823" status="corrected" lang="EN"><bibliographic-data><publication-reference fvid="146589250" ucid="EP-1277489-B1"><document-id><country>EP</country><doc-number>1277489</doc-number><kind>B1</kind><date>20140108</date><lang>EN</lang></document-id></publication-reference><application-reference ucid="EP-01921925-A" is-representative="YES"><document-id mxw-id="PAPP154851442" load-source="docdb" format="epo"><country>EP</country><doc-number>01921925</doc-number><kind>A</kind><date>20010419</date><lang>JA</lang></document-id><document-id mxw-id="PAPP172215479" load-source="docdb" format="original"><country>EP</country><doc-number>01921925.2</doc-number><date>20010419</date></document-id></application-reference><priority-claims><priority-claim mxw-id="PPC140557927" ucid="JP-0103368-W" load-source="docdb"><document-id format="epo"><country>JP</country><doc-number>0103368</doc-number><kind>W</kind><date>20010419</date></document-id></priority-claim><priority-claim mxw-id="PPC140550548" ucid="JP-2000118939-A" load-source="docdb"><document-id format="epo"><country>JP</country><doc-number>2000118939</doc-number><kind>A</kind><date>20000420</date></document-id></priority-claim><priority-claim mxw-id="PPC140558018" ucid="JP-2000236340-A" load-source="docdb"><document-id format="epo"><country>JP</country><doc-number>2000236340</doc-number><kind>A</kind><date>20000804</date></document-id></priority-claim></priority-claims><dates-of-public-availability><intention-to-grant-date><date>20130821</date></intention-to-grant-date><search-report-dispatch-date><date>20070213</date></search-report-dispatch-date></dates-of-public-availability><technical-data><classifications-ipcr><classification-ipcr mxw-id="PCL-2063117183" load-source="ipcr">A61M  29/02        20060101ALI20150331RHJP        </classification-ipcr><classification-ipcr mxw-id="PCL-2063117990" load-source="ipcr">A61F   2/915       20130101ALI20150331RHJP        </classification-ipcr><classification-ipcr mxw-id="PCL1989328048" load-source="ipcr">A61F   2/06        20130101AFI20061116BHEP        </classification-ipcr></classifications-ipcr><classifications-cpc><classification-cpc mxw-id="PCL2125000216" load-source="docdb" scheme="CPC">A61F   2/91        20130101 FI20141009BHEP        </classification-cpc><classification-cpc mxw-id="PCL2125005452" load-source="docdb" scheme="CPC">A61F2230/0054      20130101 LA20141006BHEP        </classification-cpc><classification-cpc mxw-id="PCL2125007034" load-source="docdb" scheme="CPC">A61F2002/91575     20130101 LA20141009BHEP        </classification-cpc><classification-cpc mxw-id="PCL2125017893" load-source="docdb" scheme="CPC">A61F2002/91533     20130101 LA20141009BHEP        </classification-cpc><classification-cpc mxw-id="PCL2125019574" load-source="docdb" scheme="CPC">A61F   2/915       20130101 LI20141009BHEP        </classification-cpc><classification-cpc mxw-id="PCL2125020892" load-source="docdb" scheme="CPC">A61F2002/91558     20130101 LA20141009BHEP        </classification-cpc></classifications-cpc><invention-title mxw-id="PT132372383" lang="DE" load-source="patent-office">VASKULÄRE ENDOPROTHESE</invention-title><invention-title mxw-id="PT132372384" lang="EN" load-source="patent-office">STENT</invention-title><invention-title mxw-id="PT132372385" lang="FR" load-source="patent-office">ENDOPROTHÈSE VASCULAIRE</invention-title></technical-data><parties><applicants><applicant mxw-id="PPAR919507503" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>KAWASUMI LAB INC</last-name><address><country>JP</country></address></addressbook></applicant><applicant mxw-id="PPAR919527403" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>KAWASUMI LABORATORIES, INC.</last-name></addressbook></applicant><applicant mxw-id="PPAR919530483" load-source="docdb" sequence="2" format="epo"><addressbook><last-name>IKEUCHI TAKESHI</last-name><address><country>JP</country></address></addressbook></applicant><applicant mxw-id="PPAR919526253" load-source="docdb" sequence="2" format="intermediate"><addressbook><last-name>IKEUCHI, TAKESHI</last-name></addressbook></applicant><applicant mxw-id="PPAR919535152" load-source="docdb" sequence="3" format="epo"><addressbook><last-name>IWATA HIROO</last-name><address><country>JP</country></address></addressbook></applicant><applicant mxw-id="PPAR919537747" load-source="docdb" sequence="3" format="intermediate"><addressbook><last-name>IWATA, HIROO</last-name></addressbook></applicant><applicant mxw-id="PPAR919530831" load-source="docdb" sequence="4" format="epo"><addressbook><last-name>MITSUDOU KAZUAKI</last-name><address><country>JP</country></address></addressbook></applicant><applicant mxw-id="PPAR919505784" load-source="docdb" sequence="4" format="intermediate"><addressbook><last-name>MITSUDOU, KAZUAKI</last-name></addressbook></applicant><applicant mxw-id="PPAR919538612" load-source="docdb" sequence="5" format="epo"><addressbook><last-name>MORI KOUJI</last-name><address><country>JP</country></address></addressbook></applicant><applicant mxw-id="PPAR919540904" load-source="docdb" sequence="5" format="intermediate"><addressbook><last-name>MORI, KOUJI</last-name></addressbook></applicant></applicants><inventors><inventor mxw-id="PPAR919544611" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>IKEUCHI TAKESHI</last-name><address><country>JP</country></address></addressbook></inventor><inventor mxw-id="PPAR919529285" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>IKEUCHI, TAKESHI</last-name></addressbook></inventor><inventor mxw-id="PPAR919027056" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>IKEUCHI, TAKESHI</last-name><address><street>c/o Institute for Frontier Medical Science, Kyoto University 53, Shogoin-Kawaharacho, Sakyo-ku, Kyoto-shi,</street><city>Kyoto 606-8397</city><country>JP</country></address></addressbook></inventor><inventor mxw-id="PPAR919543244" load-source="docdb" sequence="2" format="epo"><addressbook><last-name>IWATA HIROO</last-name><address><country>JP</country></address></addressbook></inventor><inventor mxw-id="PPAR919539244" load-source="docdb" sequence="2" format="intermediate"><addressbook><last-name>IWATA, HIROO</last-name></addressbook></inventor><inventor mxw-id="PPAR919027054" load-source="patent-office" sequence="2" format="original"><addressbook><last-name>IWATA, HIROO</last-name><address><street>c/o Institute for Frontier Medical Science, Kyoto University 53, Shogoin-Kawaharacho, Sakyo-ku, Kyoto-shi,</street><city>Kyoto 606-8397</city><country>JP</country></address></addressbook></inventor><inventor mxw-id="PPAR919523462" load-source="docdb" sequence="3" format="epo"><addressbook><last-name>MITSUDOU KAZUAKI</last-name><address><country>JP</country></address></addressbook></inventor><inventor mxw-id="PPAR919513146" load-source="docdb" sequence="3" format="intermediate"><addressbook><last-name>MITSUDOU, KAZUAKI</last-name></addressbook></inventor><inventor mxw-id="PPAR919027055" load-source="patent-office" sequence="3" format="original"><addressbook><last-name>MITSUDOU, KAZUAKI</last-name><address><street>597-11, Fukushima Kurashiki-shi,</street><city>OKAYAMA 710-0048</city><country>JP</country></address></addressbook></inventor><inventor mxw-id="PPAR919537919" load-source="docdb" sequence="4" format="epo"><addressbook><last-name>MORI KOUJI</last-name><address><country>JP</country></address></addressbook></inventor><inventor mxw-id="PPAR919534754" load-source="docdb" sequence="4" format="intermediate"><addressbook><last-name>MORI, KOUJI</last-name></addressbook></inventor><inventor mxw-id="PPAR919027053" load-source="patent-office" sequence="4" format="original"><addressbook><last-name>MORI, KOUJI</last-name><address><street>c/o Institute for Frontier Medical Science, Kyoto University 53, Shogoin-Kawaharacho, Sakyo-ku, Kyoto-shi,</street><city>Kyoto 606-8397</city><country>JP</country></address></addressbook></inventor><inventor mxw-id="PPAR919505352" load-source="docdb" sequence="5" format="epo"><addressbook><last-name>NOMIYAMA HIROAKI</last-name><address><country>JP</country></address></addressbook></inventor><inventor mxw-id="PPAR919541560" load-source="docdb" sequence="5" format="intermediate"><addressbook><last-name>NOMIYAMA, HIROAKI</last-name></addressbook></inventor><inventor mxw-id="PPAR919027057" load-source="patent-office" sequence="5" format="original"><addressbook><last-name>NOMIYAMA, HIROAKI</last-name><address><street>c/o Kawasumi Laboratories, Inc. 7-1, Oaza Tamada Mie-cho, Ono-gun,</street><city>Oita 879-7153</city><country>JP</country></address></addressbook></inventor><inventor mxw-id="PPAR919504931" load-source="docdb" sequence="6" format="epo"><addressbook><last-name>YOSHIKAWA YOSHIHARU</last-name><address><country>JP</country></address></addressbook></inventor><inventor mxw-id="PPAR919533613" load-source="docdb" sequence="6" format="intermediate"><addressbook><last-name>YOSHIKAWA, YOSHIHARU</last-name></addressbook></inventor><inventor mxw-id="PPAR919027058" load-source="patent-office" sequence="6" format="original"><addressbook><last-name>YOSHIKAWA, YOSHIHARU</last-name><address><street>c/o Kawasumi Laboratories, Inc. 7-1, Oaza Tamada Mie-cho, Ono-gun,</street><city>Oita 879-7153</city><country>JP</country></address></addressbook></inventor><inventor mxw-id="PPAR919536519" load-source="docdb" sequence="7" format="epo"><addressbook><last-name>WATANABE MASATOSHI</last-name><address><country>JP</country></address></addressbook></inventor><inventor mxw-id="PPAR919527288" load-source="docdb" sequence="7" format="intermediate"><addressbook><last-name>WATANABE, MASATOSHI</last-name></addressbook></inventor><inventor mxw-id="PPAR919027052" load-source="patent-office" sequence="7" format="original"><addressbook><last-name>WATANABE, MASATOSHI</last-name><address><street>c/o Kawasumi Laboratories, Inc. 7-1, Oaza Tamada Mie-cho, Ono-gun,</street><city>Oita 879-7153</city><country>JP</country></address></addressbook></inventor></inventors><assignees><assignee mxw-id="PPAR919027063" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Kawasumi Laboratories, Inc.</last-name><iid>101262515</iid><address><street>1077, Oaza Koda Yayoi</street><city>Saiki-shi, Oita 876-0121</city><country>JP</country></address></addressbook></assignee><assignee mxw-id="PPAR919027061" load-source="patent-office" sequence="2" format="original"><addressbook><last-name>Ikeuchi, Takeshi</last-name><iid>101398941</iid><address><street>c/o Institute for Frontier Medical Science, Kyoto University 53, Shogoin-Kawaharacho, Sakyo-ku, Kyoto-shi,</street><city>Kyoto 606-8397</city><country>JP</country></address></addressbook></assignee><assignee mxw-id="PPAR919027062" load-source="patent-office" sequence="3" format="original"><addressbook><last-name>Iwata, Hiroo</last-name><iid>101398942</iid><address><street>c/o Institute for Frontier Medical Science, Kyoto University 53, Shogoin-Kawaharacho, Sakyo-ku, Kyoto-shi,</street><city>Kyoto 606-8397</city><country>JP</country></address></addressbook></assignee><assignee mxw-id="PPAR919027060" load-source="patent-office" sequence="4" format="original"><addressbook><last-name>Mitsudou, Kazuaki</last-name><iid>100179845</iid><address><street>597-11, Fukushima</street><city>Kurashiki-shi, Okayama 710-0048</city><country>JP</country></address></addressbook></assignee><assignee mxw-id="PPAR919027064" load-source="patent-office" sequence="5" format="original"><addressbook><last-name>Mori, Kouji</last-name><iid>101398943</iid><address><street>c/o Institute for Frontier Medical Science, Kyoto University 53, Shogoin-Kawaharacho, Sakyo-ku, Kyoto-shi,</street><city>Kyoto 606-8397</city><country>JP</country></address></addressbook></assignee></assignees><agents><agent mxw-id="PPAR919027059" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Hering, Hartmut</last-name><iid>100002584</iid><address><street>Patentanwälte Berendt, Leyh &amp; Hering Innere Wiener Strasse 20</street><city>81667 München</city><country>DE</country></address></addressbook></agent></agents></parties><international-convention-data><pct-or-regional-filing-data ucid="JP-0103368-W"><document-id><country>JP</country><doc-number>0103368</doc-number><kind>W</kind><date>20010419</date><lang>JA</lang></document-id></pct-or-regional-filing-data><pct-or-regional-publishing-data ucid="WO-2001080936-A1"><document-id><country>WO</country><doc-number>2001080936</doc-number><kind>A1</kind><date>20011101</date><lang>JA</lang></document-id></pct-or-regional-publishing-data><designated-states><ep-contracting-states><country mxw-id="DS549876271" load-source="docdb">DE</country><country mxw-id="DS549900273" load-source="docdb">FR</country><country mxw-id="DS549876272" load-source="docdb">GB</country></ep-contracting-states></designated-states></international-convention-data></bibliographic-data><description mxw-id="PDES63961660" lang="EN" load-source="patent-office"><!-- EPO <DP n="1"> --><heading id="h0001"><u>Technical Field</u></heading><p id="p0001" num="0001">The present invention relates to improvement of a stent used to improve a narrowed portion caused in a living body such as a blood vessel and the like.</p><heading id="h0002"><u>Technical Background</u></heading><p id="p0002" num="0002">A stent is a tubular medical implement which is detained in the narrowed portion in question to ensure a required tubular region(space) by expanding the narrowed portion and the like when a tubular portion of a living body such as a blood vessel or other portions gets narrowed or clogged from obliteration. The stent is inserted into the body, with the diameter thereof small, and allowed to expand in the narrowed portion to make the diameter thereof large so that the tubular portion in question is expanded and kept in the expanded state.</p><p id="p0003" num="0003">The conventional stents, which are typically shown in <figref idrefs="f0011">Figs. 11A, 11B</figref> and <figref idrefs="f0012">Figs. 12A, 12B</figref> have the following problems. Incidentally, <figref idrefs="f0011">Fig. 11A</figref> and <figref idrefs="f0012">Fig. 12A</figref> are plan views showing the stents before expansion and <figref idrefs="f0011">Fig. 11B</figref> and <figref idrefs="f0012">Fig. 12B</figref> are plan views showing the stents after expansion.</p><p id="p0004" num="0004">In a stent 201 shown in <figref idrefs="f0011">Fig. 11A</figref>, a cell 206 constructing an annular unit 204 has a construction in which three straight line portions 207 are connected in parallel, and a curved portion 206A between each cell 206 is disposed opposite to the space 206B in the vicinity of another cell 206 constructing another annular unit 204. Because of such a construction, the stent has an appropriate radial support force (namely, as shown in <figref idrefs="f0011">Fig. 11B</figref>, a force to maintain an expansion state of the stent against the outer pressure in the direction from the blood vessel wall, when the stent is expanded and fixed on the blood vessel wall) and an excellent<!-- EPO <DP n="2"> --> flexibility. On expanding or delivering of the stent, since the stent is inserted, moving along a curved line at a bent portion of the blood vessel, a portion of the cell 206 is sometimes jutted out and caught, which makes the delivery difficult (hereinafter, this is referred to as a flare phenomenon).</p><p id="p0005" num="0005">Meanwhile, in a stent 241 shown in <figref idrefs="f0012">Fig. 12A</figref>, cells 246 constructing an annular unit 244 have a construction in which approximately or substantially &lt; shaped strut (a striate body) 247 is connected by a connecting part 245. Accordingly, it has the advantages that the stent is strong in radial support force, the approximately or substantially &lt; shaped strut 247 never warps outward during expansion of the stent or when the stent passes through the bent portion of the blood vessel, and so on. However, it has a problem of shortage of flexibility. This is because there is only one bent portion in the connecting part 245 and the length of the connecting part 245 is short, as shown in <figref idrefs="f0012">Fig. 12A</figref>.</p><p id="p0006" num="0006">As described above, the conventional stent has a problem of not having both the flexibility and the radial support force keeping in balance.</p><p id="p0007" num="0007">As a result of assiduous studies to solve the above-described problem and to provide a stent having both the flexibility and the radial support force, the present inventors have reached the present invention.</p><p id="p0008" num="0008">The conventional stents disclosed in <patcit id="pcit0001" dnum="DE29702671U"><text>DE-U-297 02 671</text></patcit> and <patcit id="pcit0002" dnum="US5911754A"><text>US-A-5 911 754</text></patcit> have a generally tubular body with annular units composed of a plurality of cells expandable radially outward from inside of the tubular body, wherein the plurality of annular units are disposed in the axial direction of said stent and connected by at least a connecting part, wherein the connecting part is formed of a bent portion connected to the cells forming adjacent annular units. Those conventional stents lack a capability of being compressed in a stable manner, owing to its poor or<!-- EPO <DP n="3"> --> inappropriate configuration and disposition of struts which compose each cell.</p><heading id="h0003"><u>Disclosure of the Invention</u></heading><p id="p0009" num="0009">The present invention is achieved from the point of view described above, and according to the present invention, the invention according to the independent claims 1 and 2 can be provided. The dependent claims 4 to 6 show advantageous further developments of the invention of any of the claims 1 and 2.</p><p id="p0010" num="0010">Especially, a stent formed into a generally or substantially tubular body with annular units composed of a plurality of cells and being expandable radially outward from inside of the tubular body, wherein the plurality of the cells are connected vertically and so arranged as to surround the central axis of the stent which forms the tubular body and thereby to construct annular units; wherein a plurality of the annular units are extended along the axis of the stent to form the tubular body in such a manner that adjacent annular units are connected at least at one portion by a connecting part; and wherein each of the cells has at least one or more bent portions, and is formed in such a manner that the angle θ of the bent portion after expansion of the tubular body until the diameter becomes at least 2.5 mm is equal to or larger than 30°.</p><p id="p0011" num="0011">Especially, the cell is formed by connecting at least one or more approximately or substantially straight line portions and curved line portions through the bent portion.</p><p id="p0012" num="0012">Especially, the cell is formed by connecting an approximately or substantially straight line portion having an acute angle X with respect to the center line in the axial direction of each stent to an approximately or substantially straight line portion disposed almost horizontally to the center line in the axial direction of the stent through the above-described bent portion.</p><p id="p0013" num="0013">Preferably, the ratio of the length of the cells to the<!-- EPO <DP n="4"> --> length of the above-described connecting part in the axial direction of the stent is formed such that when the length of the cells in the axial direction of the stent is assumed to be 100, then the length is formed to be 50 to 100.</p><p id="p0014" num="0014">Preferably, the connecting parts are arranged to be disposed at intervals of at least one connecting part, putting at least one or more spaces therebetween without disposing the connecting parts continuously and spacelessly in the radial direction of the stent.</p><p id="p0015" num="0015">Preferably, the cells are formed in a bilaterally symmetrical manner in the axial direction of the stent through the connecting parts.</p><p id="p0016" num="0016">Preferably, the cells are all formed in equal size.</p><heading id="h0004"><u>Brief Description of Drawings</u></heading><p id="p0017" num="0017"><figref idrefs="f0001">Fig. 1</figref> is a plan view showing the stent of the present invention, <figref idrefs="f0002">Fig. 2</figref> is an enlarged view of <figref idrefs="f0001">Fig. 1</figref>. <figref idrefs="f0003">Fig. 3</figref> is an enlarged view showing a state after expansion of the stent of the present invention, <figref idrefs="f0004">Fig. 4</figref> is a schematic view of a strut which constructs a cell, <figref idrefs="f0005">Fig. 5</figref> is an enlarged view when the diameter of the stent is reduced on delivering to a flood vessel, <figref idrefs="f0006">Fig. 6</figref> is a plan view showing an example of another embodiment of the stent according to the present invention, <figref idrefs="f0007">Fig. 7</figref> is a partially enlarged plan view of <figref idrefs="f0006">Fig. 6</figref>, <figref idrefs="f0008">Fig. 8</figref> is a plan view showing an example of yet another embodiment of the stent according to the present invention, <figref idrefs="f0009">Fig. 9</figref> is a partially enlarged plan view of <figref idrefs="f0008">Fig. 8</figref>, <figref idrefs="f0010">Fig. 10</figref> is an enlarged view of a reference example of the stent according to the present invention, and <figref idrefs="f0011">Figs. 11A, 11B</figref> and<!-- EPO <DP n="5"> --> <figref idrefs="f0012">Figs. 12A, 12B</figref> are plan views of conventional stents respectively.</p><p id="p0018" num="0018">In these drawings, 1, 1A and 1B indicate the stents; 4, 4A and 4B indicate the annular units; 5, 5A and 5B indicate the connecting parts; 6, 6A and 6B indicate the cells; 7 indicates an approximately or substantially straight line portion; 8 indicates a bent portion; 9 indicates a connection portion; 11, 11A, 11B and 13B indicate approximately or substantially straight line portions; 12, 12A and 12B indicate bent portions; 13 and 13A indicate curved line portions; 14 and 14A indicate small bent portions; 15 indicates an approximately or substantially straight line portion; 17 indicates an approximately or substantially &lt; shaped cell; 18 indicates an approximately or substantially S-shaped connecting part; and 19 indicates a unit part of the construction in the stents A, B.</p><heading id="h0005"><u>Preferred Embodiments of the Invention</u></heading><p id="p0019" num="0019">The present invention will be explained below in detail referring to the drawings.</p><p id="p0020" num="0020"><figref idrefs="f0001">Fig. 1</figref> is a plan view showing a stent of the present invention, <figref idrefs="f0002">Fig, 2</figref> is an enlarged view of <figref idrefs="f0001">Fig. 1</figref>, <figref idrefs="f0003">Fig. 3</figref> is an enlarged view showing a state after expansion of the stent of the present invention, and <figref idrefs="f0004">Fig. 4</figref> is a schematic view of a strut which constructs a cell.</p><p id="p0021" num="0021">The stent 1 is, as shown in <figref idrefs="f0001">Fig. 1</figref>, formed into a generally or substantially tubular body from annular units 4 consisting of a plurality of cells 6, and is expandable radially outward from inside of the tubular body wherein a plurality of the cells 6 are connected vertically and so arranged to surround the central axis C1 of the stent 1 and thereby forming the annular units 4. A plurality of the annular units 4 are extended along the axis of the stent 1 which forms the tubular body in a manner that adjacent annular units 4 are connected at least at one portion by a connecting part 5.<!-- EPO <DP n="6"> --></p><p id="p0022" num="0022">In the present invention, the cell 6 means one of constitutional units of patterns consisting the surface of the stent 1 and, as shown in <figref idrefs="f0002">Fig. 2</figref>, it includes all forms having at least one or more of bent portions 12, more concretely, bent portions 12 with acute angles X, and being constructed by connecting approximately or substantially straight line portions 11 and curved line portions 13 through the bent portion 12. In addition, when each of the cells 6 is divided vertically by the center line C2 in the axial direction of the stent, the cells 6 are formed in a vertically asymmetrical manner to the center line C2 so that the angle θ of the bent portion 12 after expansion of the tubular body is 30° or more as shown in <figref idrefs="f0003">Fig. 3</figref>, when, for example, the diameter φ of the tubular body, namely of the stent, is expanded to 2.5 mm.</p><p id="p0023" num="0023">Incidentally, the angle θ of the bent portion 12 after expansion means, as shown in <figref idrefs="f0003">Fig. 3</figref>, an angle formed at the point O on the bent portion 12 between the approximately or substantially straight line portion 11 and an approximately or substantially straight line portion 15 which is near the point O side of the curved line portion 13.</p><p id="p0024" num="0024">The cell 6 is constructed by connecting the approximately or substantially straight line portion 11 and the curved line portion 13 through the bent portion 12 as shown in <figref idrefs="f0002">Fig. 2</figref>, and it is preferable that the curved line portion 13 is constructed by forming two or more small bent portions 14 with an obtuse angle Y.</p><p id="p0025" num="0025">When the approximately or substantially straight line portion 11, the bent portion 12 and the curved line portion 13 having small bent portions 14, all of which constitute the cell 6 (hereinafter also referred to as an approximately or substantially S-shaped portion) stand more perpendicularly with respect to the central axis C1 of the stent (or the tubular body) after expansion of the stent, the radial support force of the stent becomes larger. That is, as shown in <figref idrefs="f0003">Fig. 3</figref>, the closer to 180° the angle θ of the<!-- EPO <DP n="7"> --> bent portion 12 after expansion reaches, the larger the radial support force of the stent becomes. Therefore, when designing the stent, it is preferable to design in such a manner that the angle θ of the bent portion 12 after expansion of the tubular body reaches at least 30° or more when the diameter φ of the tubular body becomes at least up to 2.5 mm, more preferably up to 3.0 mm.</p><p id="p0026" num="0026">Additionally, since these are related to the number of arrangement of the cells 6, the number of radial disposition of the cells 6 is preferably 4 or more. Furthermore, when the diameter φ of the tubular body or the stent after expansion is 3.0 mm or more, it is desirable to dispose the cells at least 6 pieces or more, preferably 6 pieces to 12 pieces.</p><p id="p0027" num="0027">In the axial direction of the stent, it is desirable to dispose 3 pieces or more, more preferably, 4 pieces to 8 pieces per 10 mm of the length in the axial direction of the stent, and when the diameter of the stent reaches the diameter on target for the stent expansion (spec diameter, for example, φ= 3.0 mm or φ= 4.0 mm), it is desirable, for example, to design the angle θ of the bent portion 12 after expansion to be at least 30° or more, preferably between 45° and 140°, more preferably between 45° and 120° as described previously.</p><p id="p0028" num="0028">It should be noted that, as for the diameter on target (targeted diameter), it is effective for the better radial support force of the stent to design the angle θ after expansion to be near 180°, for example, over 140°, as described above. However, it is not favorable because of the following problems such that the amount of deformation of the bent portion 12 becomes too large to maintain the strength of it in a favorable state, and the reduction in total length of the stent accompanied by the expansion (hereinafter referred to as foreshortening) becomes too large to make an easy positioning of the stent when detaining the stent.</p><p id="p0029" num="0029">It is preferable for the shape of the strut of the<!-- EPO <DP n="8"> --> cell 6 to form asymmetrically with respect to the center line C2 of respective cells in the axial direction of the stent as shown in <figref idrefs="f0004">Fig. 4b</figref>, rather than to form symmetrically as shown in <figref idrefs="f0004">Fig. 4a</figref>. This is because that asymmetrical formation of the strut makes the relative length of the whole strut longer (for instance, when <figref idrefs="f0004">Fig. 4a</figref> is compared with <figref idrefs="f0004">Fig. 4b</figref>, it is always found to be 2 a &lt; c + d), enhances the expandability of the stent itself, and enhances the suppression effect of the foreshortening.</p><p id="p0030" num="0030">The connecting part 5 between cell 6 and 6 in the stent 1 is constructed by having at least two or more of bent portions and by connecting the bent portions 8 and 8 to both sides of the central approximately or substantially straight line portion 7, and the end portions of the bent portions 8 are connected to the end portions of the cells 6 and 6 which construct respectively different (adjacent) annular units 4 and 4 through the connection portions 9 and 9, as shown in <figref idrefs="f0002">Fig. 2</figref>.</p><p id="p0031" num="0031">Incidentally, the connecting part 5 is connected to both sides of the cells 6 and 6 in a bilaterally asymmetrical manner, as shown in <figref idrefs="f0002">Fig. 2</figref>.</p><p id="p0032" num="0032">As for the length of the connecting part 5, it is preferable for the total length of the approximately or substantially straight line portion 7 and the bent portions 8 and 8 to be 1 mm or more because the flexibility of the stent is believed that the longer the total length of the stent the more the flexibility is improved. However, if it is too long, the connecting part 5 in an approximately or substantially S shape becomes proportionally large, which makes vertically adjacent connecting parts 5 interfere in each other, thereby conversely spoiling the flexibility, when the stent is mounted on a balloon catheter (the diameter of the stent may be sometimes reduced a little on the balloon catheter), or when the stent is bent along the blood vessel during passing through the bent portion of the blood vessel. Therefore, it is preferable for the total length of the connecting part to<!-- EPO <DP n="9"> --> be 1 mm or more, preferably 1 mm to 2 mm. It is further desirable for R (radius) of an arc constructing the bent portion 8 to be 0.05 mm or more, preferably 0.05 mm to 0.2 mm because of the above reason.</p><p id="p0033" num="0033">Further, in the present invention, as shown in <figref idrefs="f0002">Fig. 2</figref>, with the ratio of the length 6L to the length 5L, it is preferable for the length 5L of the connecting part 5 in the axial direction of the stent to be 50 to 100 on the basis that the length 6L of the cells 6 in the axial direction of the stent is assumed to be 100. For convenience of design, it is more preferable to form in the length of 50 to 90. Thereby, the flare phenomenon after expansion of the stent or during delivery can be suppressed and at the same time, flexibility can be given to the stent itself.</p><p id="p0034" num="0034">The characteristics of the pattern of the stent 1 according to the present invention is as follows:
<ul><li>For example, as shown in <figref idrefs="f0002">Fig. 2</figref>, the cells 6 are disposed or placed respectively asymmetrically with respect to the center line C2 in the axial direction of the stent through the connecting part 5. However, in the axial direction of the stent, they are disposed in the same direction and at the same height. In other words, the cells 6 in the axial direction of the stent are disposed so as to align and lie on top of one another if the cells 6 are shifted in the axial direction of the stent from the nth line (column) to the (n + 1)th line (column), and the cells 6 in the same line (the same annular unit) are disposed in the same direction in the radial direction of the stent so as to align and lie on top of one another if they are slid vertically from their present positions to upward or downward in the same line. Incidentally, though approximately or substantially straight line portion 11 of each cell is in substantially horizontal (substantially in parallel) to the center line C2 respectively, it may be inclined at some angles in a range not to be less than 30° of the angle θ of the bent portion 12 after expansion.</li></ul><!-- EPO <DP n="10"> --></p><p id="p0035" num="0035">Further, though the connecting parts 5 are also disposed asymmetrically in the axial direction of the stent through the cell 6, they are disposed facing in the same direction in the axial direction of the stent and at the same height. In other words, the connecting parts 5 in the axial direction of the stent are seen to be disposed so as to align and lie on top of one another if the connecting parts 5 are shifted in the axial direction of the stent from the nth line to the (n + 1)th line, and the connecting parts in the same line are seen to be disposed in the same direction in the radial direction of the stent so as to align and lie on top of one another if they are slid vertically from their present positions to upward or downward of the same line.</p><p id="p0036" num="0036">In the stent of the present invention, the width of the strut constructing the cell 6 is preferably wider than the width of the strut constructing the connecting part 5, and the heights of the cell 6 and the connecting part 5 in the axial direction of the stent are preferably disposed in such a manner that both are shifted to each other so as to be at a different height from each other, not to be at the same height.</p><p id="p0037" num="0037">As described above, in the stent 1 of the present invention, by specifying the angle θ of the bent portion 12 after expansion, the ratio of the length 6L in the axial direction of the stent of the cell 6 to the length 5L in the axial direction of the stent of the connecting part, the shape and size of the connecting part 5 and the cell 6, the disposition (pattern) in the radial direction and the axial direction of the stent of the connecting part 5 and the cell 6 as above, the cells 6 and the connecting parts 5 do not align and do not lie respectively on top of one another three-dimensionally in the radial direction of the stent when the diameter of the stent 1 is reduced during delivering to the blood vessel as shown in <figref idrefs="f0005">Fig. 5</figref>. That is, when the diameter of the stent 1 is reduced as shown in <figref idrefs="f0005">Fig. 5</figref>, they are formed to fit in the space S in the radial direction of<!-- EPO <DP n="11"> --> the stent existing between each of the cells 6 and the connecting parts 5 as shown in <figref idrefs="f0002">Fig. 2</figref>.</p><p id="p0038" num="0038"><figref idrefs="f0006">Fig. 6</figref> and <figref idrefs="f0008">Fig. 8</figref> are plan views showing examples of other embodiments of the present invention and <figref idrefs="f0007">Fig. 7</figref> and <figref idrefs="f0009">Fig. 9</figref> are partially enlarged plan views of <figref idrefs="f0006">Fig. 6</figref> and <figref idrefs="f0008">Fig. 8</figref> respectively.</p><p id="p0039" num="0039">The stent 1A shown in <figref idrefs="f0006">Fig. 6</figref> and <figref idrefs="f0007">Fig. 7</figref> is basically the same excepting only the following point when compared with the stent 1 shown in <figref idrefs="f0001">Fig. 1</figref>. That is, (a) each of the cells 6A is constructed by connecting approximately or substantially straight line portion 11A having an acute angle X with respect to respective center line C2 in the axial direction of the stent 1A to the curved line portion 13A through the bent portion 12A (while the stent 1 is constructed by connecting approximately or substantially straight line portion 11 disposed almost horizontally (substantially in parallel) with respect to respective center line C2 in the axial direction of the stent 1 to the curved line portion 13 through the bent portion 12), (b) the cells 6A are disposed in a bilaterally symmetrical manner in the axial direction of the stent 1A through the connecting part 5A, (c) the cells 6A in the axial direction of the stent 1A are disposed to align and lie on top of one another when seen from the cells in the nth line to the cells in the (n + 2)th line, on every other line in the axial direction of the stent 1A. Since respective other construction members and the definitions thereof are substantially the same as those in the stent 1, the detailed explanation thereof will be omitted here.</p><p id="p0040" num="0040">Furthermore, the stent 1B shown in <figref idrefs="f0008">Fig. 8</figref> and <figref idrefs="f0009">Fig. 9</figref> is different from the stents 1 and 1A shown in <figref idrefs="f0001">Fig. 1</figref>, <figref idrefs="f0006">Fig. 6</figref> and <figref idrefs="f0007">Fig. 7</figref> only in the point that (a) each of the cells 6B is constructed by connecting an approximately or substantially straight line portion 11B having an acute angle X with respect to respective center lines C2 in the axial direction of the stent 1B to an approximately or substantially straight<!-- EPO <DP n="12"> --> line portion 13B disposed almost horizontally (substantially in parallel) with the center line C2 in the axial direction of the stent 1 through the bent portion 12B (while in the stent 1, and stent 1A, each of the cells 6 and 6A is constructed by connecting the approximately or substantially straight line portion 11, 11A to the curved line portion 13, 13A through the bent portion 12). Though the following points of (b) respective cells 6B are disposed in a bilaterally symmetrical manner in the axial direction of the stent 1B through the connecting part 5B, and (c) the cells 6B in the axial direction of the stent 1B are disposed to align and lie on top of one another when seen in the axial direction of the stent 1B from the cells in the nth line to those in the (n + 2)th line, on every other line in the axial direction of the stent 1B are different from the stent 1, the stent 1B is substantially the same with the points of (b) and (c) as those in the stent 1A. Since respective other construction members and the definitions thereof are substantially the same as those in the stent 1 and the stent 1A, the detailed explanation thereof will be omitted here.</p><p id="p0041" num="0041">In the stents 1, 1A and 1B shown in the above-described <figref idrefs="f0001">Fig. 1</figref>, <figref idrefs="f0006">Fig. 6</figref> and <figref idrefs="f0008">Fig. 8</figref> of the present invention, though the connecting parts 5, 5A and 5B of the cells 6, 6A and 6B constructing respective annular units 4, 4A and 4B are disposed continuously without space in the radial direction of the stents 1, 1A and 1B, they may be disposed with at least one or more spaces in the radial direction. Thus, by disposing the connecting parts suitably with one space apart or one or two spaces apart, the whole stents 1, 1A, 1B become more flexible so that the deliverability to branched blood vessels is expected to improve.</p><p id="p0042" num="0042">As a material constructing the stents 1, 1A, 1B of the present invention, well-known materials itself can be used without any limitation and a metal pipe made of, for example, stainless steel such as SUS 316L and the like, a shape memory alloy such as Ti-Ni alloy, Cu-Al-Mn alloy and so<!-- EPO <DP n="13"> --> on, Cu-Zn alloy, Ni-Al alloy, titan, titan alloy, tantalum, tantalum alloy, platinum, platinum alloy, tungsten and tungsten alloy is used to form the stent by a laser processing method or other processing method.</p><p id="p0043" num="0043">On the surface of the stent formed with these metals, a polymeric material having compatibility with a living body such as polyurethane, polyvinyl pyrrolidine, or polyvinyl alcohol, or a material in which the above polymeric material is fixed with a physiologically active substance such as heparin, urokinase and the like by chemical bonding, and a material in which the above polymeric material is mixed with an antithrombosis medicine such as argatroban, cilostazol, sarpogrelate HCl, and so on may be applied as a coating.</p><heading id="h0006"><u>Example 1</u></heading><p id="p0044" num="0044">In the stent A (B) constructed by unit parts 19 of the construction consisting of approximately or substantially &lt; shaped cells 17 and approximately or substantially S-shaped connecting parts 18, as shown in <figref idrefs="f0010">Fig. 10</figref>, in order to evaluate difference in radial support force due to the difference of the angle after expansion, the stent A (the number of arrangement: 8) and the stent B (the number of arrangement: 6) which are different in the number of arrangement of the unit parts 19 of the construction in the circumferential direction, are prepared as below, and respective radial support forces are evaluated and compared.
<tables id="tabl0001" num="0001"><table frame="none"><tgroup cols="3" colsep="0" rowsep="0"><colspec colnum="1" colname="col1" colwidth="16mm"/><colspec colnum="2" colname="col2" colwidth="67mm"/><colspec colnum="3" colname="col3" colwidth="18mm"/><tbody><row><entry>stent A:</entry><entry>the number of the unit parts 19 to be arranged</entry><entry>8</entry></row><row><entry/><entry>strut width of the cell 17</entry><entry>0.12 mm</entry></row><row><entry/><entry>1 <i>θ</i> angle after expansion by 3 mm</entry><entry>60°</entry></row><row><entry>stent B:</entry><entry>the number of the unit parts 19 to be arranged</entry><entry>6</entry></row><row><entry/><entry>strut width of the cell 17</entry><entry>0.12 mm</entry></row><row><entry/><entry>1 <i>θ</i> angle after expansion by 3 mm</entry><entry>81°</entry></row></tbody></tgroup></table></tables></p><p id="p0045" num="0045">The evaluation is carried out by expanding respective stents in a silicone tube disposed in a chamber by 3 mm of the diameter φ. After detaining them,<!-- EPO <DP n="14"> --> change in the outer diameter of the stents while applying pressure in the chamber with air is measured to evaluate. The measurement result is shown in Table 1.
<tables id="tabl0002" num="0002"><table frame="all"><title><u>Table 1</u></title><tgroup cols="3"><colspec colnum="1" colname="col1" colwidth="108mm"/><colspec colnum="2" colname="col2" colwidth="23mm"/><colspec colnum="3" colname="col3" colwidth="23mm"/><thead><row><entry namest="col1" nameend="col3" align="center" valign="middle">(measurement result of the radial support force)</entry></row><row><entry align="center" valign="middle"/><entry align="center" valign="middle">stent A</entry><entry align="center" valign="middle">stent B</entry></row></thead><tbody><row><entry align="center" valign="middle">amount of change in the outer diameter when applying pressure of 0.02 MPa</entry><entry align="center" valign="middle">-0.07 mm</entry><entry align="center" valign="middle">-0.04 mm</entry></row></tbody></tgroup></table></tables></p><p id="p0046" num="0046">As clearly shown in Table 1, while the amount of change in the outer diameter is -0.04 mm (which means the outer diameter is shortened by 0.04 mm) in the stent B having a larger angle (1θ) after expansion, the amount of change in the outer diameter is -0.07 mm (which means the outer diamter is shortened by 0.07 mm) in the stent A. Thus, it was confirmed that the stent B is smaller in the amount of change in the outer diameter and larger in the radial support force.</p><heading id="h0007"><u>Example 2</u></heading><p id="p0047" num="0047">The stent 1 shown in <figref idrefs="f0001">Fig. 1</figref> was prepared, and the radial support force was compared with conventional stents 201 (<figref idrefs="f0011">Fig. 11</figref>) and 241 (<figref idrefs="f0012">Fig. 12</figref>) and the flexibility was compared with the stent 201 to evaluate. The evaluation of the radial support force was carried out in the same manner as in the example 1, and the flexibility was evaluated by the 4 point bending test. The measurement result of the radial support force is shown in Table 2 and the measurement result of the flexibility is shown in Table 3.
<tables id="tabl0003" num="0003"><table frame="all"><title><u>Table 2</u></title><tgroup cols="4"><colspec colnum="1" colname="col1" colwidth="107mm"/><colspec colnum="2" colname="col2" colwidth="21mm"/><colspec colnum="3" colname="col3" colwidth="19mm"/><colspec colnum="4" colname="col4" colwidth="21mm"/><thead><row><entry namest="col1" nameend="col4" align="center" valign="middle">(measurement result of the radial support force)</entry></row><row><entry align="center" valign="middle"/><entry align="center" valign="middle">stent 1</entry><entry align="center" valign="middle">stent 201</entry><entry align="center" valign="middle">stent 241</entry></row></thead><tbody><row><entry align="center" valign="middle">amount of change in the outer diameter when applying pressure of 0.02 MPa</entry><entry align="center" valign="middle">-0.026 mm</entry><entry align="center" valign="middle">-0.05 mm</entry><entry align="center" valign="middle">-0.030 mm</entry></row></tbody></tgroup></table></tables><!-- EPO <DP n="15"> -->
<tables id="tabl0004" num="0004"><table frame="all"><title><u>Table 3</u></title><tgroup cols="3"><colspec colnum="1" colname="col1" colwidth="27mm"/><colspec colnum="2" colname="col2" colwidth="20mm"/><colspec colnum="3" colname="col3" colwidth="20mm"/><thead><row><entry namest="col1" nameend="col3" align="center" valign="top">(measurement result of the flexibility)</entry></row><row><entry align="center" valign="top"/><entry align="center" valign="top">stent 1</entry><entry align="center" valign="top">stent 201</entry></row></thead><tbody><row><entry align="center">flexural strength</entry><entry align="center">11.7N·mm</entry><entry align="center">17.1N·mm</entry></row></tbody></tgroup></table></tables></p><p id="p0048" num="0048">As clearly shown in Table 2, it is recognized that the amount of change in the outer diameter of the stent 1 of the present invention is smaller than those of both the stent 201 and the stent 241, and, as is clear from the result in. Table 3, the flexural strength is smaller than that of the stent 201. As described above, the stent 1 of the present invention is recognized to be a stent having both a high radial support force and high flexibility.</p><heading id="h0008"><u>Example 3</u></heading><p id="p0049" num="0049">The radial support force and the flexibility of the stent 1A shown in <figref idrefs="f0006">Fig. 6</figref> (<figref idrefs="f0007">Fig. 7</figref>) and the stent 1B shown in <figref idrefs="f0008">Fig. 8</figref> (<figref idrefs="f0009">Fig. 9</figref>) were measured and evaluated in the same manner as in Example 1 and Example 2. The measurement result of the radial support force is shown in Table 4 and the measurement result of the flexibility is shown in Table 5. As is clear from Tables, it is recognized that substantially the same results as in the stent 1 are obtained also as for the stent 1A and the stent 1B.
<tables id="tabl0005" num="0005"><table frame="all"><title><u>Table 4</u></title><tgroup cols="5"><colspec colnum="1" colname="col1" colwidth="90mm"/><colspec colnum="2" colname="col2" colwidth="20mm"/><colspec colnum="3" colname="col3" colwidth="20mm"/><colspec colnum="4" colname="col4" colwidth="18mm"/><colspec colnum="5" colname="col5" colwidth="20mm"/><thead><row><entry namest="col1" nameend="col5" align="center" valign="middle">(measurement result of the radial support force</entry></row><row><entry align="center" valign="middle"/><entry align="center" valign="middle">stent 1A</entry><entry align="center" valign="middle">stent 1B</entry><entry align="center" valign="middle">stent 201</entry><entry align="center" valign="middle">stent 241</entry></row></thead><tbody><row><entry align="center" valign="middle">amount of change in the outer diameter when applying pressure of 0.02 MPa</entry><entry align="center" valign="middle">-0.033 mm</entry><entry align="center" valign="middle">-0.031 mm</entry><entry align="center" valign="middle">-0.05 mm</entry><entry align="center" valign="middle">-0.030 mm</entry></row></tbody></tgroup></table></tables><!-- EPO <DP n="16"> -->
<tables id="tabl0006" num="0006"><table frame="all"><title><u>Table 5</u></title><tgroup cols="4"><colspec colnum="1" colname="col1" colwidth="29mm"/><colspec colnum="2" colname="col2" colwidth="19mm"/><colspec colnum="3" colname="col3" colwidth="19mm"/><colspec colnum="4" colname="col4" colwidth="19mm"/><thead><row><entry namest="col1" nameend="col4" align="center" valign="top">(measurement result of the flexibility)</entry></row><row><entry align="center" valign="top"/><entry align="center" valign="top">stent 1A</entry><entry align="center" valign="top">stent 1B</entry><entry align="center" valign="top">stent 201</entry></row></thead><tbody><row><entry align="center">flexural strength</entry><entry align="center">13.7N·mm</entry><entry align="center">14.3N·mm</entry><entry align="center">17.1N·mm</entry></row></tbody></tgroup></table></tables></p><heading id="h0009"><u>Example 4</u></heading><p id="p0050" num="0050">As for the stents 1, 1A, 1B in the present invention, the foreshortening values when the diameter φ of the stents were expanded to 3.0 mm were measured. The measurement was carried out in such a manner that each stent length (referred to as L1) before expansion and the corresponding stent length (referred to as L2) after expansion to 3.0 mmφ were measured and the reduction ratios of the total length were calculated with the following formula to have the foreshortening value. <maths id="math0001" num=""><math display="block"><mi>Foreshortening value</mi><mo>=</mo><mfenced separators=""><mfenced separators=""><mi mathvariant="normal">L</mi><mo>⁢</mo><mn mathvariant="normal">1</mn><mo>-</mo><mi mathvariant="normal">L</mi><mo>⁢</mo><mn mathvariant="normal">2</mn></mfenced><mo>/</mo><mi mathvariant="normal">L</mi><mo>⁢</mo><mn mathvariant="normal">1</mn></mfenced><mo>×</mo><mn mathvariant="normal">100</mn></math><img id="ib0001" file="imgb0001.tif" wi="111" he="4" img-content="math" img-format="tif"/></maths></p><p id="p0051" num="0051">As comparison examples, the same measurements were made for the stent 201 and the stent 241. The result is shown in Table 6.
<tables id="tabl0007" num="0007"><table frame="all"><title><u>Table 6</u></title><tgroup cols="6"><colspec colnum="1" colname="col1" colwidth="34mm"/><colspec colnum="2" colname="col2" colwidth="14mm"/><colspec colnum="3" colname="col3" colwidth="16mm"/><colspec colnum="4" colname="col4" colwidth="16mm"/><colspec colnum="5" colname="col5" colwidth="18mm"/><colspec colnum="6" colname="col6" colwidth="18mm"/><thead><row><entry align="center" valign="top"/><entry align="center" valign="top">stent 1</entry><entry align="center" valign="top">stent 1A</entry><entry align="center" valign="top">stent 1B</entry><entry align="center" valign="top">stent 201</entry><entry align="center" valign="top">stent 241</entry></row></thead><tbody><row><entry align="center">foreshortening value</entry><entry align="center">1.5%</entry><entry align="center">1.5%</entry><entry align="center">3%</entry><entry align="center">5.6%</entry><entry align="center">5.6%</entry></row></tbody></tgroup></table></tables></p><p id="p0052" num="0052">As is clear from Table 6, the foreshortening values of all stents 1, 1A and 1B of the present invention are recognized to be far smaller than those of the conventional stents 201 and 241.</p><heading id="h0010"><u>Industrial Utility</u></heading><p id="p0053" num="0053">The stent of the present invention can ensure sufficiently both of high flexibility and a high radial support force and at the same time enhance the expandability of the blood vessel and suppress the foreshortening and the flare phenomenon, so that it can be preferably used as a stent to expand a narrowed portion of the blood vessel to ensure a necessary and important tubular region.</p></description><claims mxw-id="PCLM56987720" lang="DE" load-source="patent-office"><!-- EPO <DP n="21"> --><claim id="c-de-01-0001" num="0001"><claim-text>Stent (1), der in einen allgemeinen oder im Wesentlichen rohrförmigen Körper mit kreisringförmigen Einheiten ausgebildet ist, die aus einer Vielzahl von Zellen gebildet sind und von innerhalb des rohrförmigen Körpers radial nach außen ausdehnbar sind,
<claim-text>wobei die Vielzahl der Zellen (6) vertikal verbunden ist und derart angeordnet ist, dass sie die zentrale Achse (C1) des Stents (1) umgeben, der den rohrförmigen Körper ausbildet, um dadurch die kreisringförmigen Einheiten (4) auszubilden;</claim-text>
<claim-text>wobei die Vielzahl der kreisringförmigen Einheiten (4) in der axialen Richtung des Stents (1) angeordnet ist und die benachbarten kreisringförmigen Einheiten (4) wenigstens an einem Teilbereich durch ein Verbindungsteil (5) verbunden sind;</claim-text>
<claim-text>wobei das Verbindungsteil (5) aus einem gebogenen Teilbereich (8) mit wenigstens zwei oder mehreren Bögen und einem annähernd oder im Wesentlichen geradlinigen Teilbereich (7) als Fortsetzung zu dem gebogenen Teilbereich (8) ausgebildet ist, wobei die Enden des gebogenen Teilbereichs (8) jeweils mit dem linken Teilbereich und dem rechten Teilbereich der Zellen (6) verbunden sind, die jeweils benachbarte kreisringförmige Einheiten (1) ausbilden;</claim-text>
<claim-text><b>dadurch gekennzeichnet, dass</b>:
<claim-text>(A) jede der Zellen aus zwei Streben gebildet ist, wobei eine Strebe aus einem annähernd oder im Wesentlichen geradlinigen Teilbereich (SLP-Strebe) gebildet ist und wobei die andere Strebe aus einem bogenlinigen Teilbereich (CLP-Strebe) gebildet ist und wobei eine Strebe in der axialen Richtung angeordnet ist, um dadurch eine Basisstrebe (BS-Strebe) zu sein, und wobei die andere Strebe unter einem spitzen Winkel (X) in Bezug auf die axiale Richtung angeordnet ist, um dadurch einen Biegestrebe (BN-Strebe) zu sein, und<br/>
wobei:
<claim-text>jede der Zellen (6) eine Mittenlinie (C2) in der axialen Richtung des Stents (1) hat und aus zwei Streben ausgebildet ist, indem folgendes<!-- EPO <DP n="22"> --> verbunden wird:
<claim-text>(i) der annähernd oder im Wesentlichen geradlinige Teilbereich (11) (SLP-Strebe), der nahezu horizontal zur Mittenlinie (C2) oder axialen Richtung angeordnet ist, und</claim-text>
<claim-text>(ii) der bogenlinige Teilbereich (13) (CLP-Strebe), der unter einem spitzen Winkel (X) in Bezug auf die Mittenlinie (C2) oder die axiale Richtung angeordnet ist, über einen gebogenen Teilbereich (12),</claim-text></claim-text>
<claim-text>wobei ein annähernd oder im Wesentlichen geradliniger Teilbereich (15), der einen Teil des bogenlinigen Teilbereichs (13) (CLP-Strebe) ausbildet und benachbart zu dem gebogenen Teilbereich (12) ist, mit dem annähernd oder im Wesentlichen geradlinigen Teilbereich (11) (SLP-Strebe), der nahezu horizontal zur Mittenlinie (C2) oder axialen Richtung des Stents (1) angeordnet ist, über den gebogenen Teilbereich (12) verbunden ist, und wobei dadurch</claim-text>
<claim-text>die Zellen (6) derart ausgebildet sind, dass sie vertikal asymmetrisch zur Mittenlinie (C2) ausgebildet sind, wenn sie durch die Mittenlinie (C2) in der axialen Richtung des Stents (1) vertikal geteilt sind, wodurch eine Kompression des Stents (1) ausgeführt wird, während die SLP-Strebe, die die Basisstrebe (BS-Strebe) ist, die axiale Richtung beibehält, und die CLP-Strebe, die die Biegestrebe (BN-Strebe) ist, in Richtung zu der Basisstrebe (BS-Strebe) gebogen wird,</claim-text>
<claim-text>und</claim-text></claim-text><claim-text>(B) wobei der Stent (1) zu wenigstens einem Durchmesser (ϕ) von 2.5 mm ausdehnbar ist, wobei der Stent (1) auf eine Weise ausgebildet ist, dass der zwischen dem annähernd oder im Wesentlichen geradlinigen Teilbereich (15) benachbart zu dem gebogenen Teilbereich (12) und dem annähernd oder im Wesentlichen geradlinigen Teilbereich (11) (SLP-Strebe) ausgebildete Winkel (θ) nach einem Ausdehnen 30°-140° ist, wenn der Durchmesser (ϕ) des kreisringförmigen Körpers auf 2.5 mm ausgedehnt ist.</claim-text></claim-text></claim-text></claim><claim id="c-de-01-0002" num="0002"><claim-text>Stent (1A), der in einen allgemeinen oder wesentlichen rohrförmigen Körper mit kreisringförmigen Einheiten ausgebildet ist, die aus einer Vielzahl von Zellen gebildet sind und von innerhalb des rohrförmigen Körpers radial nach außen ausdehnbar sind,
<claim-text>wobei die Vielzahl der Zellen (6A) vertikal verbunden ist und derart angeordnet ist, dass sie die zentrale Achse (C1) des Stents (1A) umgeben,<!-- EPO <DP n="23"> --> der den rohrförmigen Körper ausbildet, um dadurch die kreisringförmigen Einheiten (4A) auszubilden;</claim-text>
<claim-text>wobei die Vielzahl der kreisringförmigen Einheiten (4A) in der axialen Richtung des Stents (1A) angeordnet, ist und die benachbarten kreisringförmigen Einheiten (4A) wenigstens an einem Teilbereich durch ein Verbindungsteil (5A) verbunden sind;</claim-text>
<claim-text>wobei das Verbindungsteil (5A) aus einem gebogenen Teilbereich (8A) mit wenigstens zwei oder mehreren Bögen und einem annähernd oder im Wesentlichen geradlinigen Teilbereich (7A) als Fortsetzung zu dem gebogenen Teilbereich (8A) ausgebildet ist, wobei die Enden des gebogenen Teilbereichs (8A) jeweils mit dem linken Teilbereich und dem rechten Teilbereich der Zellen (6A) verbunden sind, die jeweils benachbarte kreisringförmige Einheiten (1A) ausbilden;</claim-text>
<claim-text><b>dadurch gekennzeichnet, dass</b>:
<claim-text>(A) jede der Zellen aus zwei Streben gebildet ist, wobei eine Strebe aus einem annähernd oder im Wesentlichen geradlinigen Teilbereich (SLP-Strebe) gebildet ist und wobei die andere Strebe aus einem bogenlinigen Teilbereich (CLP-Strebe) gebildet ist und wobei eine Strebe in der axialen Richtung angeordnet ist, um dadurch eine Basisstrebe (BS-Strebe) zu sein, und wobei die andere Strebe unter einem spitzen Winkel (X) in Bezug auf die axiale Richtung angeordnet ist, um dadurch einen Biegestrebe (BN-Strebe) zu sein, und<br/>
wobei:
<claim-text>jede der Zellen (6A) eine Mittenlinie (C2) in der axialen Richtung des Stents (1A) hat und aus zwei Streben ausgebildet ist, indem folgendes verbunden wird:
<claim-text>(i) der bogenlinige Teilbereich (13A) (CLP-Strebe), der nahezu horizontal zu der Mittenlinie (C2) oder axialen Richtung angeordnet ist, und</claim-text>
<claim-text>(ii) der annähernd oder im Wesentlichen geradlinige Teilbereich (11A) (SLP-Strebe), der unter einem spitzen Winkel (X) in Bezug auf die Mittenlinie (C2) oder die axiale Richtung angeordnet ist, über einen gebogenen Teilbereich (12A),</claim-text></claim-text>
<claim-text>wobei eine annähernd oder im Wesentlichen geradliniger Teilbereich (15A), der einen Teil des bogenlinigen Teilbereichs (13A) (CLP-Strebe) ausbildet und benachbart zu dem gebogenen Teilbereich (12A) ist, mit dem annähernd oder im Wesentlichen geradlinigen Teilbereich<!-- EPO <DP n="24"> --> (11A) (SLP-Strebe), der unter dem spitzen Winkel (X) in Bezug auf die Mittenlinie (C2) angeordnet ist, verbunden ist, und wobei dadurch</claim-text>
<claim-text>die Zellen (6A) derart ausgebildet sind, dass sie vertikal asymmetrisch zu der Mittenlinie (C2) ausgebildet sind, wenn sie durch die Mittenlinie (C2) in der axialen Richtung des Stents (1A) vertikal geteilt sind, wodurch eine Kompression des Stents (1) ausgeführt wird, während die CLP-Strebe, die die Basisstrebe (BS-Strebe) ist, die axiale Richtung beibehält, und die SLP-Strebe, die die Biegestrebe (BN-Strebe) ist, in Richtung zu der Basisstrebe (BS-Strebe) gebogen wird,</claim-text>
<claim-text>und</claim-text></claim-text><claim-text>(B) wobei der Stent (1) zu wenigstens einem Durchmesser (ϕ) von 2.5 mm ausdehnbar ist, wobei der Stent (1) auf eine Weise ausgebildet ist, dass der zwischen dem annähernd oder im Wesentlichen geradlinigen Teilbereich (15A) benachbart zu dem gebogenen Teilbereich (12A) und dem annähernd oder im Wesentlichen geradlinigen Teilbereich (11A) (SLP-Strebe) ausgebildete Winkel (θ) nach einem Ausdehnen 30°-140° ist, wenn der Durchmesser (ϕ) des kreisringförmigen Körpers auf 2.5 mm ausgedehnt ist.</claim-text></claim-text></claim-text></claim><claim id="c-de-01-0003" num="0003"><claim-text>Stent (1, 1A) nach einem der vorangehenden Ansprüche, wobei das Verhältnis der Länge (6L, 6AL) der Zelle in der axialen Richtung des Stents zu der Länge (5L, 5AL) des Verbindungsteils (5, 5A) in der axialen Richtung des Stents so ausgebildet ist, dass dann, wenn als Basis angenommen wird, dass die Länge (6L, 6AL) der Zelle (6, 6A) in der axialen Richtung des Stents 100 ist, die Länge (5L, 5AL) des Verbindungsteils (5, 5A) in der axialen Richtung des Stents so ausgebildet ist, dass sie 50 bis 100 ist.</claim-text></claim><claim id="c-de-01-0004" num="0004"><claim-text>Stent (1, 1A) nach einem der vorangehenden Ansprüche, wobei die Verbindungsteile (5, 5A) derart angeordnet sind, dass sie in Intervallen von wenigstens einem Verbindungsteil angeordnet sind, was wenigstens einen oder mehrere Räume dazwischen einbringt, ohne die Verbindungsteile in der radialen Richtung des Stents (1, 1A) kontinuierlich und ohne Raum anzuordnen.</claim-text></claim><claim id="c-de-01-0005" num="0005"><claim-text>Stent (1, 1A) nach einem der vorangehenden Ansprüche, wobei die Zellen (6A) über die Verbindungsteile (5A) auf eine disymmetrische Weise<!-- EPO <DP n="25"> --> in der axialen Richtung des Stents ausgebildet sind.</claim-text></claim><claim id="c-de-01-0006" num="0006"><claim-text>Stent (1, 1A) nach einem der vorangehenden Ansprüche, wobei die Zellen (6, 6A) alle in gleicher Größe ausgebildet sind.</claim-text></claim></claims><claims mxw-id="PCLM56987721" lang="EN" load-source="patent-office"><!-- EPO <DP n="17"> --><claim id="c-en-01-0001" num="0001"><claim-text>A stent (1) formed into a generally or substantially tubular body with annular units composed of a plurality of cells and being expandable radially outward from inside of the tubular body,<br/>
wherein the plurality of the cells (6) are connected vertically and so arranged as to surround the central axis (C1) of the stent (1) which forms the tubular body and thereby forming the annular units (4);<br/>
wherein the plurality of said annular units (4) are disposed in the axial direction of said stent (1), and said adjacent annular units (4) are connected at least at one portion by a connecting part (5);<br/>
wherein said connecting part (5) is formed of a bent portion (8) having at least two or more arcs and an approximately or substantially straight line portion (7) continuing to the bent portion (8), the ends of said bent portion (8) are respectively connected to the left portion and the right portion of said cells (6) forming adjacent annular units (1) respectively;<br/>
<b>characterized in that</b>:
<claim-text>(A) each of said cells being composed of two struts, one strut being composed of an approximately or substantially straight line portion (SLP-Strut) and the other strut being composed of a curved line portion (CLP-strut), and one strut being disposed in the axial direction thus comprising a base strut (BS-strut), and the other strut being disposed at an acute angle (X) with respect to the axial direction thus comprising a bending strut (BN-strut), and,<br/>
wherein;<br/>
each of said cells (6) has a center line (C2) in the axial direction of the stent (1) and is formed of two struts by connecting
<claim-text>(i) the approximately or substantially straight line portion (11) (SLP-Strut) disposed almost horizontally to the center line (C2) or axial direction and,<!-- EPO <DP n="18"> --></claim-text>
<claim-text>(ii) the curved line portion (13)(CLP-strut) disposed at an acute angle (X) with respect to the center line (C2) or the axial direction through a bent portion (12),<br/>
wherein an approximately or substantially straight line portion (15) forming a part of said curved line portion (13) (CLP-strut) and being adjacent to said bent portion (12) is connected to the approximately or substantially straight line portion (11) (SLP-Strut) disposed almost horizontally to the center line (C2) in the axial direction of the stent through said bent portion (12), and thereby<br/>
said cells (6) are being formed to be vertically asymmetrical to the center line (C2) when divided vertically by the center line (C2) in the axial direction of the stent (1), thereby compression of the stent is carried out while said SLP-strut comprising the base strut (BS-Strut) maintaining the axial direction, and said CLP-Strut comprising the bending strut (BN-Strut) being bent toward the base strut (BS-Strut),<br/>
and</claim-text></claim-text>
<claim-text>(B) said stent (1) being expandable to at least diameter (ϕ) 2.5 mm, wherein the stent (1) is being formed in a manner that the angle (θ) formed between said approximately or substantially straight line portion (15) adjacent to said bent portion (12) and said approximately or substantially straight line portion (11) (SLP-Strut) is 30°-140° after expansion when the diameter (ϕ) of said annular body is expanded to 2.5 mm.</claim-text></claim-text></claim><claim id="c-en-01-0002" num="0002"><claim-text>A stent (1A) formed into a generally or substantially tubular body with annular units composed of a plurality of cells and being expandable radially outward from inside of the tubular body,
<claim-text>wherein the plurality of the cells (6A) are connected vertically and so arranged as to surround the central axis (C1) of the stent (1A) which forms the tubular body and thereby forming the annular units (4A);</claim-text>
<claim-text>wherein the plurality of said annular units (4A) are disposed in the axial direction of said stent (1A), and said adjacent annular units (4A) are connected at least at one portion by a connecting part (5A);</claim-text>
<claim-text>wherein said connecting part (5A) is formed of a bent portion (8A) having at least two or more arcs and an approximately or substantially straight line portion (7A) continuing to the bent portion (8A), the ends of said bent portion (8A) are respectively connected to the left portion and the<!-- EPO <DP n="19"> --> right portion of said cells (6A) forming adjacent annular units (1A) respectively; <b>characterized in that</b>:
<claim-text>(A) each of said cells being composed of two struts, one strut being composed of an approximately or substantially straight line portion (SLP-Strut)and the other strut being composed of a curved line portion (CLP-strut), and one strut being disposed in the axial direction thus comprising a base strut (BS-strut), and the other strut being disposed at an acute angle (X) with respect to the axial direction thus comprising a bending strut (BN-strut), and,<br/>
wherein;<br/>
each of said cells (6A) has a center line (C2) in the axial direction of the stent (1A) and is formed of two struts by connecting
<claim-text>(i) the curved line portion (13A) (CLP-strut) disposed almost horizontally to the center line (C2) or axial direction and,</claim-text>
<claim-text>(ii) the approximately or substantially straight line portion (11A) (SLP-strut) disposed at an acute angle (X) with respect to the center line (C2) or the axial direction through a bent portion (12A),<br/>
wherein an approximately or substantially straight line portion (15A) forming a part of said curved line portion (13A) (CLP-strut) and being adjacent to said bent portion (12A) is connected to the approximately or substantially straight line portion (11A) (SLP-strut) being disposed at said acute angle (X) with respect to the center line (C2), and thereby<br/>
said cells (6A) are being formed to be vertically asymmetrical to the center line (C2) when divided vertically by the center line (C2) in the axial direction of the stent (1A), thereby compression of the stent is carried out while said CLP-Strut comprising the base strut (BS-Strut) maintaining the axial direction, and said SLP-stent comprising the bending strut (BN-Strut) being bent toward the base strut (BS-Strut),<br/>
and</claim-text></claim-text>
<claim-text>(B) said stent (1A) being expandable to at least diameter (ϕ) 2.5 mm wherein the stent (1A) is being formed in a manner that the angle (θ) formed between said approximately or substantially straight line portion (15A) adjacent to said bent portion (12A) and said approximately or substantially straight line portion (11A) (SLP-strut) 30°-140° after expansion when the diameter (ϕ) of said annular body is expanded to 2.5 mm.</claim-text></claim-text><!-- EPO <DP n="20"> --></claim-text></claim><claim id="c-en-01-0003" num="0003"><claim-text>The stent (1, 1A) according to any of the preceding claims, wherein the ratio of the length (6L, 6AL) of said cell in the axial direction of the stent to the length (5L, 5AL) of said connecting part (5, 5A) in the axial direction of the stent is formed such that when the length (6L, 6AL) of said cell (6, 6A) in the axial direction of the stent is assumed, as a basis, to be 100, then the length (5L, 5AL) of said connecting part in the axial direction of the stent is formed to be 50 to 100.</claim-text></claim><claim id="c-en-01-0004" num="0004"><claim-text>The stent (1, 1A) according to any of the preceding claims, wherein said connecting parts (5, 5A) are arranged to be disposed at intervals of at least one connecting part, putting at least one or more spaces therebetween without disposing the connecting parts continuously and spacelessly in the radial direction of the stent (1, 1A).</claim-text></claim><claim id="c-en-01-0005" num="0005"><claim-text>The stent (1, 1A) according to any of the preceding claims, wherein said cells (6A) are formed in a bilaterally symmetrical manner in the axial direction of the stent through the connecting parts (5A).</claim-text></claim><claim id="c-en-01-0006" num="0006"><claim-text>The stent (1, 1A) according to any of the preceding claims, wherein said cells (6, 6A) are all formed in equal size.</claim-text></claim></claims><claims mxw-id="PCLM56987722" lang="FR" load-source="patent-office"><!-- EPO <DP n="26"> --><claim id="c-fr-01-0001" num="0001"><claim-text>Endoprothèse (1) formée dans un corps généralement ou essentiellement tubulaire avec des unités annulaires, qui sont composées d'une pluralité de cellules et expansibles radialement vers l'extérieur depuis l'intérieur du corps tubulaire,
<claim-text>les cellules de la pluralité des cellules (6) étant reliées verticalement et disposées de façon à entourer l'axe central (C1) de l'endoprothèse (1), qui forme le corps tubulaire, formant ainsi les unités annulaires (4),</claim-text>
<claim-text>les unités annulaires de la pluralité des unités annulaires (4) étant disposées dans le sens axial de ladite endoprothèse (1) et reliées via une partie de liaison (5) à une portion au moins,</claim-text>
<claim-text>ladite partie liaison (5) étant formée par une portion cintrée (8) ayant au moins deux arcs ou plus et une portion de ligne approximativement ou essentiellement droite (7) continuant vers la portion cintrée (8), les extrémités de ladite portion cintrée (8) étant respectivement reliées à la portion gauche et la portion droite desdites cellules (6) formant respectivement des unités annulaires adjacentes (1),</claim-text>
<claim-text><b>caractérisée en ce que</b>:
<claim-text>(A) chacune desdites cellules est composée de deux supports, l'un étant composé d'une portion de ligne approximativement ou essentiellement droite (support SLP) et l'autre d'une portion de ligne incurvée (support CLP), l'un étant disposé dans le sens axial, comprenant, de ce fait, un support de base (support BS) et l'autre étant disposé de manière à former un angle aigu (X) par rapport au sens axial, comprenant, de ce fait, un support cintrant (support BN) et<br/>
chacune desdites cellules (6) présente une ligne centrale (C2), qui s'étend dans le sens axial de l'endoprothèse (1) et est formée de deux supports en reliant entre elles<!-- EPO <DP n="27"> -->
<claim-text>(i) la portion de ligne approximativement ou essentiellement droite (11) (support SLP) disposée pratiquement horizontalement par rapport à la ligne centrale (C2) ou au sens axial, et</claim-text>
<claim-text>(ii) la portion de ligne incurvée (13) (support CLP) disposée de manière à former un angle aigu (X) par rapport à la ligne centrale (C2) ou au sens axial par l'intermédiaire d'une portion cintrée (12),</claim-text>
une portion de ligne approximativement ou essentiellement droite (15), qui forme une partie de ladite portion de ligne incurvée (13) (support CLP) et est adjacente à ladite portion cintrée (12), étant reliée à la portion de ligne approximativement ou essentiellement droite (11) (support SLP), qui est disposée pratiquement horizontalement par rapport à la ligne centrale (C2) dans le sens axial de l'endoprothèse par l'intermédiaire de ladite portion cintrée (12) et par conséquent<br/>
lesdites cellules (6) étant formées de manière à être verticalement symétriques par rapport à la ligne centrale (C2), lorsqu'elles sont divisées verticalement par la ligne centrale (C2) dans le sens axial de l'endoprothèse (1), par conséquent l'endoprothèse est comprimée pendant que ledit support SLP comprenant le support de base (support BS) maintient le sens axial et ledit support CLP comprenant le support cintrant (support BN) est cintré envers le support de base (support BS),<br/>
et</claim-text><claim-text>(B) ladite endoprothèse (1) est expansible jusqu'à un diamètre (ϕ) de 2,5 mm au moins, ladite endoprothèse (1) étant formée de manière que l'angle (θ) formé entre ladite portion de ligne approximativement ou essentiellement droite (15) adjacente à ladite portion cintrée (12) et ladite portion de ligne approximativement ou essentiellement droite (11) (support SLP) est de 30° à 140° après l'expansion, lorsque le diamètre (ϕ) dudit corps annulaire est expansé jusqu'à 2,5 mm.</claim-text></claim-text></claim-text></claim><claim id="c-fr-01-0002" num="0002"><claim-text>Endoprothèse (1) formée dans un corps généralement ou essentiellement tubulaire avec des unités annulaires, qui sont composées d'une pluralité de cellules et expansibles radialement vers l'extérieur depuis l'intérieur du corps tubulaire,<!-- EPO <DP n="28"> -->
<claim-text>les cellules de la pluralité des cellules (6A) étant reliées verticalement et disposées de façon à entourer l'axe central (C1) de l'endoprothèse (1A), qui forme le corps tubulaire, formant ainsi les unités annulaires (4A),</claim-text>
<claim-text>les unités annulaires de la pluralité des unités annulaires (4A) étant disposées dans le sens axial de ladite endoprothèse (1A) et lesdites unités annulaires adjacentes (4A) étant reliées via une partie de liaison (5A) à une portion au moins,</claim-text>
<claim-text>ladite partie liaison (5A) étant formée par une portion cintrée (8A) ayant au moins deux arcs ou plus et une portion de ligne approximativement ou essentiellement droite (7A) continuant vers la portion cintrée (8A), les extrémités de ladite portion cintrée (8A) étant respectivement reliées à la portion gauche et la portion droite desdites cellules (6A) formant respectivement des unités annulaires adjacentes (1A),</claim-text>
<claim-text><b>caractérisée en ce que</b>:
<claim-text>(A) chacune desdites cellules est composée de deux supports, l'un étant composé d'une portion de ligne approximativement ou essentiellement droite (support SLP) et l'autre d'une portion de ligne incurvée (support CLP), l'un étant disposé dans le sens axial, comprenant, de ce fait, un support de base (support BS) et l'autre étant disposé de manière à former un angle aigu (X) par rapport au sens axial, comprenant, de ce fait, un support cintrant (support BN) et<br/>
chacune desdites cellules (6A) présente une ligne centrale (C2), qui s'étend dans le sens axial de l'endoprothèse (1A) et est formée de deux supports en reliant entre elles
<claim-text>(i) la portion de ligne incurvée (13A) (support CLP) disposée pratiquement horizontalement par rapport à la ligne centrale (C2) ou au sens axial et</claim-text>
<claim-text>(ii) la portion de ligne approximativement ou essentiellement droite (11A) (support SLP) disposée de manière à former un angle aigu (X) par rapport à la ligne centrale (C2) ou au sens axial par l'intermédiaire d'une portion cintrée (12A),</claim-text>
une portion de ligne approximativement ou essentiellement droite (15A), qui forme une partie de ladite portion de ligne incurvée (13A) (support CLP) et est adjacente à ladite portion cintrée (12A), étant reliée à la portion de<!-- EPO <DP n="29"> --> ligne approximativement ou essentiellement droite (11A) (support SLP), qui est disposée de manière à former ledit angle aigu (X) par rapport à la ligne centrale (C2) et, par conséquent<br/>
lesdites cellules (6A) étant formées de manière à être verticalement symétriques par rapport à la ligne centrale (C2) lorsqu'elles sont divisées verticalement par la ligne centrale (C2) dans le sens axial de l'endoprothèse (1A), par conséquent l'endoprothèse est comprimée pendant que ledit support CLP comprenant le support de base (support BS) maintient le sens axial et ladite endoprothèse SLP comprenant le support cintrant (support BN) est cintrée envers le support de base (support BS),<br/>
et</claim-text><claim-text>(B) ladite endoprothèse (1A) est expansible jusqu'à un diamètre (ϕ) de 2,5 mm au moins, ladite endoprothèse (1) étant formée de manière que l'angle (θ) formé entre ladite portion de ligne approximativement ou essentiellement droite (15A) adjacente à ladite portion cintrée (12A) et ladite portion de ligne approximativement ou essentiellement droite (11A) (support SLP) est de 30° à 140° après l'expansion, lorsque le diamètre (ϕ) dudit corps annulaire est expansé jusqu'à 2,5 mm.</claim-text></claim-text></claim-text></claim><claim id="c-fr-01-0003" num="0003"><claim-text>Endoprothèse (1, 1A) suivant une quelconque des revendications précédentes, le rapport entre la longueur (6L, 6AL) de ladite cellule dans le sens axial de l'endoprothèse et la longueur (5L, 5AL) de ladite partie de liaison (5, 5A) dans le sens axial de l'endoprothèse est conçu tel que lorsque la longueur (6L, 6AL) de ladite cellule (6, 6A) dans le sens axial de l'endoprothèse est supposée, comme base, être 100, alors la longueur (5L, 5AL) de ladite partie de liaison dans le sens axial de l'endoprothèse est de 50 à 100.</claim-text></claim><claim id="c-fr-01-0004" num="0004"><claim-text>Endoprothèse (1, 1A) suivant une quelconque des revendications précédentes, lesdites parties de liaison (5, 5A) étant agencées afin d'être disposées à des intervalles d'au moins une partie de liaison, en y insérant au moins un espace ou plus sans disposer les parties de liaison de façon continue et sans espace dans le sens radial de l'endoprothèse (1, 1A).<!-- EPO <DP n="30"> --></claim-text></claim><claim id="c-fr-01-0005" num="0005"><claim-text>Endoprothèse (1, 1A) suivant une quelconque des revendications précédentes, lesdites cellules (6A) étant formées de manière bilatéralement symétrique dans le sens axial de l'endoprothèse par l'intermédiaire des parties de liaison (5A).</claim-text></claim><claim id="c-fr-01-0006" num="0006"><claim-text>Endoprothèse (1, 1A) suivant une quelconque des revendications précédentes, lesdites cellules (6, 6A) étant toutes conçues de taille identique.</claim-text></claim></claims><drawings mxw-id="PDW16672831" load-source="patent-office"><!-- EPO <DP n="31"> --><figure id="f0001" num="1"><img id="if0001" file="imgf0001.tif" wi="109" he="233" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="32"> --><figure id="f0002" num="2"><img id="if0002" file="imgf0002.tif" wi="146" he="230" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="33"> --><figure id="f0003" num="3"><img id="if0003" file="imgf0003.tif" wi="120" he="179" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="34"> --><figure id="f0004" num="4(a),4(b)"><img id="if0004" file="imgf0004.tif" wi="91" he="204" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="35"> --><figure id="f0005" num="5"><img id="if0005" file="imgf0005.tif" wi="108" he="193" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="36"> --><figure id="f0006" num="6"><img id="if0006" file="imgf0006.tif" wi="98" he="223" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="37"> --><figure id="f0007" num="7"><img id="if0007" file="imgf0007.tif" wi="156" he="218" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="38"> --><figure id="f0008" num="8"><img id="if0008" file="imgf0008.tif" wi="100" he="232" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="39"> --><figure id="f0009" num="9"><img id="if0009" file="imgf0009.tif" wi="136" he="221" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="40"> --><figure id="f0010" num="10"><img id="if0010" file="imgf0010.tif" wi="98" he="187" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="41"> --><figure id="f0011" num="11(A),11(B)"><img id="if0011" file="imgf0011.tif" wi="142" he="222" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="42"> --><figure id="f0012" num="12(A),12(B)"><img id="if0012" file="imgf0012.tif" wi="153" he="217" img-content="drawing" img-format="tif"/></figure></drawings><copyright>User acknowledges that Fairview Research LLC and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws.  User acquires no ownership rights to this xml including but not limited to its format.  User hereby accepts the terms and conditions of the Licence Agreement</copyright></patent-document>
